期刊
CANCER IMMUNOLOGY IMMUNOTHERAPY
卷 60, 期 9, 页码 1257-1268出版社
SPRINGER
DOI: 10.1007/s00262-011-1027-1
关键词
MHC class I; Reversible defects; Metastases; Immunotherapy
资金
- MEC [1631]
- FIS-Research Contract [CP03/0111]
- Fundacion Progreso y Salud
- FIS [CP03/0111, PI 08/1265, RETIC RD 06/020]
- Consejeria de Salud
- Junta de Andalucia in Spain [CTS-143, CTS-695, CTS-3952]
- European Community [LSHC-CT-2004-503306, 2004/c158, 18234]
- Kureha Chemical Industry, Tokyo, Japan
Tumor or metastatic cells lose MHC class I (MHC-I) expression during cancer progression as an escape mechanism from immune surveillance. These defects in MHC-I may be reversible by cytokines or different agents (soft lesions) or irreversible due to structural defects (hard lesions). The nature of these MHC-I alterations might determine the success or failure of immunotherapy treatments. In this study, we have used an MHC-I-positive murine fibrosarcoma tumor clone, GR9-A7, which generates multiple lung and lymph node metastases with reversible MHC-I alterations after treatment with IFN-gamma. Four different antitumor treatments were carried out after primary tumor excision to determine their capacity to inhibit spontaneous metastatic colonization of the GR9-A7 tumor clone. We found that 2 different immunotherapy protocols (CpG plus autologous irradiated-GR9-A7 cells and protein-bound polysaccharide K (PSK) and 1 chemoimmunotherapy (docetaxel plus PSK) induced eradication of metastases. In contrast, chemotherapy with docetaxel alone produced only partial reduction in the number of metastases. Flow cytometric analysis of lymphocyte populations showed an immunosuppression in GR9-A7 tumor-bearing host, which could be reverted by immunotherapy treatments. Our results suggest that irreversible or reversible MHC-I alterations in tumor target cells may determine its progression or regression independently of the type of immunotherapy used.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据